Kaplan-Meier survival curve.

Twenty-seven (29%) of 93 patients were alive at 29 months of follow up. Median survival was 16 months (95% CI: 11.8-21.9 months). Nineteen (61%) of 31 responders were still alive 21 to 34 months after alemtuzumab therapy, with median survival of 32 months. In total, 21 (68%) of 31 responders were still alive at the end of the study, and 42 (45%) of 93 patients survived more than 18 months.